Track topics on Twitter Track topics that are important to you
Cognetix is a private drug discovery and development company located in Salt Lake City, Utah, focused on commercializing conopeptide-based pharmaceuticals. Conopeptides are bioactive peptides in the venom of marine cone snails. The Company is currently in clinical trials investigating its lead compound, CGX-1160, for the treatment of chronic intractable pain. The Company has a strong drug discovery program in the field of pain, powered by the most extensive conopeptide libraries and conopeptide-related intellectual property position in the world. Cognetix has an exclusive worldwide license to conopeptide-related technology arising from research at the University of Utah and The Salk Institute. It maintains laboratory facilities in both Salt Lake City, Utah and Ivoryton, Connecticut
421 Wakara Way, Suite 201
Salt Lake City
United States of America
We have published hundreds of Cognetix, Inc. news stories on BioPortfolio along with dozens of Cognetix, Inc. Clinical Trials and PubMed Articles about Cognetix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cognetix, Inc. Companies in our database. You can also find out about relevant Cognetix, Inc. Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...